Cargando…

Eshel A, Sharon I, Nagler A, et al. Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis. Blood Adv. 2022;6(2):568-573.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043927/ https://www.ncbi.nlm.nih.gov/pubmed/35446385 http://dx.doi.org/10.1182/bloodadvances.2022007476

Ejemplares similares

Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
Publicado: (2022)

Shouval R, Fein JA, Cho C, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6(5):1525-1535.
Publicado: (2022)

Vo P, Gooley, TA, Carpenter PA, et al. Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Adv. 2022;6(11):3220-3229.
Publicado: (2022)

Deen D, Butter F, Daniels DE, et al. Identification of the transcription factor MAZ as a regulator of erythropoiesis. Blood Adv. 2021;5(15):3002-3015.
Publicado: (2022)

Duque-Afonso J, Ewald S, Ihorst G, et al. The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Adv. 2021;5(21):4327-4337.
Publicado: (2022)

Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085-3092.
Publicado: (2022)

Kahn JM, Brazauskas R, Tecca HR, et al. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020;4(9):2084-2094.
Publicado: (2022)

Olin RL, Fretham C, Pasquini MC, et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4(12):2810-2820.
Publicado: (2022)

Koh J, Jang I, Mun S, et al. Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv. 2021;5(20):3919-3930.
Publicado: (2022)

Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.
Publicado: (2022)

Bornhauser B, Cario G, Rinaldi A, et al. The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Adv. 2020;4(17):4052-4064.
Publicado: (2022)

Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016.
Publicado: (2022)

Xu S, Wang S, Xing S, et al. KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2. Blood Adv. 2021;5(17):3241-3253.
Publicado: (2022)

Samra B, Khoury JD, Morita K, et al. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021;5(20):3913-3918.
Publicado: (2022)

Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6(4):1296-1308.
Publicado: (2022)

Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
Publicado: (2023)

Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785.
Publicado: (2023)

van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.
Publicado: (2023)

Singh A, Brandow AM, Panepinto JA. COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Blood Adv. 2021;5(7):1915-1921.
Publicado: (2022)

Crouch S, Painter D, Barrans SL, et al. Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network. Blood Adv. 2022;6(21):5716-5731.
Publicado: (2023)

Erratum to: Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease
Publicado: (2021)

Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.
Publicado: (2023)

Lisi V, Blanchard È, Vladovsky M, et al. Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia. Blood Adv. 2022;6(17):5160-5164.
Publicado: (2023)

Nawas MT, Sanchez-Escamilla M, Devlin SM, et al. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation. Blood Adv. 2022;6(22):5898-5907.
Publicado: (2023)

Edição de Abril de 2022, vol. 118(42), págs. 797-857
Publicado: (2022)

Kudo K, Kubota Y, Toki T, et al. Childhood acute myeloid leukemia with 5q deletion and HNRNPH1-MLLT10 fusion: the first case report. Blood Adv. 2022;6(10):3162-3166.
Publicado: (2022)

Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
Publicado: (2022)

Wang et al (J Infect Dis 2016; 213:1380–7)
Publicado: (2016)

Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
Publicado: (2023)

Uy GL, Newell LF, Lin TL, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022;6(17):4989-4993.
Publicado: (2023)

Nicol MP et al (Clin Infect Dis 2013; 57:e18–21)
Publicado: (2014)

Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847.
Publicado: (2023)

Erratum: A meta-analysis on age-associated changes in blood DNA methylation: results from an original analysis pipeline for Infinium 450k data
por: Bacalini, Maria Giulia, et al.
Publicado: (2016)

Erratum for the Research Article: “Origin of uranium isotope variations in early solar nebula condensates” by F. L. H. Tissot, N. Dauphas, L. Grossman
Publicado: (2016)

Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195.
Publicado: (2015)

Schleicher RI, Reichenbach F, Kraft P, et al. Platelets induce apoptosis via membrane-bound FasL. Blood. 2015;126(12):1483-1493.
Publicado: (2016)

Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714.
Publicado: (2019)

Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037.
Publicado: (2021)

Sharon Tseng Final Summer Student Report: Monitoring Vibrations Using an FPGA
por: Tseng, Sharon
Publicado: (2016)

Two Cases of Israeli Spotted Fever with Purpura Fulminans, Sharon District, Israel
por: Cohen, Regev, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c4cm2fnb4dsvm5rss3ud10kv2d